JP2023539361A5 - - Google Patents

Info

Publication number
JP2023539361A5
JP2023539361A5 JP2023514397A JP2023514397A JP2023539361A5 JP 2023539361 A5 JP2023539361 A5 JP 2023539361A5 JP 2023514397 A JP2023514397 A JP 2023514397A JP 2023514397 A JP2023514397 A JP 2023514397A JP 2023539361 A5 JP2023539361 A5 JP 2023539361A5
Authority
JP
Japan
Prior art keywords
cells
population
culture
approximately
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023514397A
Other languages
English (en)
Japanese (ja)
Other versions
JP7824934B2 (ja
JP2023539361A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/071330 external-priority patent/WO2022051749A1/en
Publication of JP2023539361A publication Critical patent/JP2023539361A/ja
Publication of JP2023539361A5 publication Critical patent/JP2023539361A5/ja
Application granted granted Critical
Publication of JP7824934B2 publication Critical patent/JP7824934B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023514397A 2020-09-02 2021-08-31 操作されたナチュラルキラー細胞の増殖および細胞毒性の増強およびその使用 Active JP7824934B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073671P 2020-09-02 2020-09-02
US63/073,671 2020-09-02
PCT/US2021/071330 WO2022051749A1 (en) 2020-09-02 2021-08-31 Enhanced expansion and cytotoxicity of engineered natural killer cells and uses thereof

Publications (3)

Publication Number Publication Date
JP2023539361A JP2023539361A (ja) 2023-09-13
JP2023539361A5 true JP2023539361A5 (cg-RX-API-DMAC7.html) 2024-09-10
JP7824934B2 JP7824934B2 (ja) 2026-03-05

Family

ID=80492150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514397A Active JP7824934B2 (ja) 2020-09-02 2021-08-31 操作されたナチュラルキラー細胞の増殖および細胞毒性の増強およびその使用

Country Status (9)

Country Link
US (1) US20230265390A1 (cg-RX-API-DMAC7.html)
EP (1) EP4204560A4 (cg-RX-API-DMAC7.html)
JP (1) JP7824934B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230058167A (cg-RX-API-DMAC7.html)
CN (1) CN116568805A (cg-RX-API-DMAC7.html)
AU (1) AU2021337000A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191047A1 (cg-RX-API-DMAC7.html)
IL (1) IL300903A (cg-RX-API-DMAC7.html)
WO (1) WO2022051749A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
WO2024163619A1 (en) * 2023-02-01 2024-08-08 Nkarta, Inc. Methods for expanding immune cells and related compositions and uses thereof
KR102669705B1 (ko) * 2023-02-24 2024-06-10 이엔셀 주식회사 제대혈 유래 자연 살해 세포의 확장배양방법
KR20240175366A (ko) * 2023-06-12 2024-12-20 한국화학연구원 Nk 세포의 증식 촉진 또는 활성화용 조성물 및 그의 용도
WO2025220989A1 (ko) * 2024-04-16 2025-10-23 주식회사 유씨아이테라퓨틱스 자연살해세포의 증폭 및 형질 도입 효율 증진용 피더 세포

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3487991B1 (en) * 2016-07-25 2022-09-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing modified natural killer cells and methods of use
US10300089B2 (en) * 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
AU2018227583B2 (en) * 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
MX2019011570A (es) * 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
WO2019165121A1 (en) * 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
CN113226340A (zh) * 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
AU2020321354A1 (en) * 2019-07-31 2022-03-03 Nkarta, Inc. Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells

Similar Documents

Publication Publication Date Title
JP2022542399A5 (cg-RX-API-DMAC7.html)
Shimasaki et al. Expanded and armed natural killer cells for cancer treatment
Tarazona et al. Current progress in NK cell biology and NK cell-based cancer immunotherapy
JP2022184852A5 (cg-RX-API-DMAC7.html)
Ljunggren et al. Prospects for the use of NK cells in immunotherapy of human cancer
Locatelli et al. Natural killer cells in the treatment of high-risk acute leukaemia
Lim et al. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo
Pesce et al. Human NK cell subsets redistribution in pathological conditions: a role for CCR7 receptor
RU2019128544A (ru) Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
Van Ostaijen-Ten Dam et al. Preparation of cytokine-activated NK cells for use in adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential
JP2019523001A5 (cg-RX-API-DMAC7.html)
JP2017512484A5 (cg-RX-API-DMAC7.html)
JP2018500944A5 (cg-RX-API-DMAC7.html)
JP2016509839A5 (cg-RX-API-DMAC7.html)
JP2021522839A5 (cg-RX-API-DMAC7.html)
JP2012521215A5 (cg-RX-API-DMAC7.html)
JP5118624B2 (ja) 新規なヒトt細胞集団
JP7572371B2 (ja) 養子移入療法(Adoptive transfer therapies)におけるTリンパ球及びNK細胞の拡大増殖及び分化のための方法
Van Caeneghem et al. Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities
JP2024513522A5 (cg-RX-API-DMAC7.html)
Yang et al. Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia
CN115058393B (zh) 一种包被刺激物、培养试剂盒和自然杀伤细胞的培养方法
Klingemann Development and testing of NK cell lines
Lu et al. CD16+ CD56− NK cells in the peripheral blood of cord blood transplant recipients: a unique subset of NK cells possibly associated with graft‐versus‐leukemia effect
WO2001075072A2 (en) PRODUCTION OF TcR GAMMA DELTA T CELLS